From Financial Modeling Prep: 2025-04-07 09:00:00

Nurix Therapeutics, Inc. (NASDAQ: NRIX) is a biotech company focused on protein degradation therapies, facing competition in the industry. Analysts predict an EPS of -$0.72 and revenue of $13 million for the upcoming quarterly earnings, showing improvement from last year. The financial metrics reveal profitability challenges but a strong current ratio of 6.46.



Read more at Financial Modeling Prep:: Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Pr…